Request Demo
Last update 29 Aug 2025
Shanghai Chemowanbang Biopharma Co., Ltd.
Last update 29 Aug 2025
Overview
Tags
Hemic and Lymphatic Diseases
Immune System Diseases
Digestive System Disorders
Fc fusion protein
Interferons
Biosimilar
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
CTR20200792
评价单次皮下注射重组人促红素注射液（CHO细胞）在健康成年男性受试者体内单中心、开放、随机、两制剂、两周期、两序列、双交叉生物等效性研究
[Translation] A single-center, open-label, randomized, two-drug, two-cycle, two-sequence, double-crossover bioequivalence study to evaluate the bioequivalence of a single subcutaneous injection of recombinant human erythropoietin injection (CHO cells) in healthy adult male subjects
CTR20191961
重组人促红素-HyFc融合蛋白注射液在健康志愿者中的耐受性、药代动力学和药效学特征的Ⅰa期临床试验。
[Translation] A phase Ia clinical trial of the tolerability, pharmacokinetics and pharmacodynamics of recombinant human erythropoietin-HyFc fusion protein injection in healthy volunteers.
CTR20190398
评价单次皮下注射重组人促红素注射液在健康受试者体内单中心、开放、随机、两制剂生物等效性研究（预试验）
[Translation] A single-center, open-label, randomized, two-dose bioequivalence study to evaluate the bioequivalence of a single subcutaneous injection of recombinant human erythropoietin injection in healthy subjects (preliminary study)
100 Clinical Results associated with Shanghai Chemowanbang Biopharma Co., Ltd.
Login to view more data
Login to view more data
100 Deals associated with Shanghai Chemowanbang Biopharma Co., Ltd.
Login to view more data
100 Translational Medicine associated with Shanghai Chemowanbang Biopharma Co., Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 13 Sep 2025
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 3
1
3
Approved
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free